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Primary hyperparathyroidism is a common endocrinological disorder. In rare circumstances, it is associated with
familial syndromes, such as multiple endocrine neoplasia type 1. This syndrome is caused by a germline mutation
in the multiple endocrine neoplasia type 1 gene encoding the tumor-suppressor protein menin. Usually, primary
hyperparathyroidism is the initial clinical expression in carriers of multiple endocrine neoplasia type 1 mutations,
occurring in more than 90% of patients and appearing at a young age (20–25 years). Multiple endocrine
neoplasia type 1/primary hyperparathyroidism is generally accompanied by multiglandular disease, clinically
manifesting with hypercalcemia, although it can remain asymptomatic for a long time and consequently not
always be recognized early. Surgery is the recommended treatment. The goal of this short review is to discuss the
timing of surgery in patients when primary hyperparathyroidism is associated with multiple endocrine neoplasia
type 1.
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INTRODUCTION
Primary hyperparathyroidism (PHPT) is a condition
caused by hyperfunction of the parathyroid tissue, usually
involving only one gland. However, it is often multi-
glandular when expressed within complex hereditary
syndromes, such as multiple endocrine neoplasia type 1
(MEN1), MEN2A, familial isolated hyperparathyroidism,
autosomal dominant mild hyperparathyroidism, neonatal
severe hyperparathyroidism, familial hypocalciuric hyper-
calcemia, and the hyperparathyroidism–jaw tumor syn-
drome (1,2).
Surgery is the principal treatment for these forms of
familial PHPT, apart from in cases associated with familial
hypocalciuric hypercalcemia. In this short review, we
discuss the timing of surgery in patients with PHPT
associated with MEN1.
MEN1 SYNDROME
MEN1 syndrome (MIM#131100) is a rare hereditary
cancer syndrome encompassing a variety of more than 20
endocrine and nonendocrine tumors (3). MEN1 is relatively
rare (approximately 1 in 30,000) and the definition of MEN1
that is widely used is ‘‘a case with tumor in two of the three
principal organs: anterior pituitary, parathyroid, and enter-
opancreatic endocrine tissue’’ (4,5).
Familial MEN1 is defined as one MEN1 case plus one
first-degree relative with one of the three principal tumors
or involvement of only one organ and a MEN1 disease-
causing germline mutation (6).
The MEN1 gene was identified in 1997 and is the only
gene known to be associated with this syndrome (7,8).
Genetic testing with direct sequencing of the MEN1 gene is
widely available and provides the best method of diagnosis;
it can detect MEN1 gene mutations in about 90% of patients
with MEN1 within 4–6 weeks. Germline MEN1 mutation is
identifiable in 90% of typical MEN1 families and in only
6–10% of isolated cases (9). Some patients without an
identified mutation may have large deletions that are not
recognized by polymerase chain reaction or have mutations
in the tested open reading frame and intron–exon junctions
(10,11). Recently it became possible to search for large
deletions or duplications in the MEN1 gene using the
multiplex ligation-dependent probe amplification assay
(12).
Genetic testing makes possible: (a) the identification of
asymptomatic adults with a family history of MEN1; (b) the
prenatal diagnosis of MEN1; and (c) the elimination of non-
carriers by clinical screening (13).
MEN1-PHPT
PHPT in MEN1 is the most common form of endocrino-
pathy and it represents 2–4% of all forms of PHPT. It is the
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141earliest endocrine expression in most patients, clinically
relevant neoplasia is uncommon before puberty, occurring
in 90% of MEN1 individuals between 20 and 25 years of
age, although mild-to-moderate hyperparathyroidism often
emerges during adolescence with mild hypercalcemia.
All individuals are affected by 50 years of age (14). Its
progression is usually gradual but significant hypercalcemia
is occasionally evident in early adolescence.
The signs and symptoms of hypercalcemia include kidney
stones, low bone mass, constipation, nausea, vomiting,
polyuria, dehydration, hypercalciuria, hypertension, shor-
tened QT interval, lethargy, depression, confusion, and
anorexia (14).
The medical therapies of MEN1-related PHPT include
drugs such as bisphosphonates and calcimimetics. Currently,
these drugs have a limited role, being used primarily in the
presence of recurrent PHPT or when there are contrain-
dications to surgery (15–17).
The treatment of choice in MEN1-related PHPT is surgery
but in this regard some considerations deserve attention.
Age
The age of onset of familial hyperparathyroidism is
clearly anticipated at two–three decades compared with
the non-syndromic form. The occurrence of hyperparathyr-
oidism at a young age carries a high suspicion of MEN1
syndrome, supported by family history and an association
with other endocrinopathies typical of MEN1 syndrome
(13). Preclinical diagnosis of MEN1 gene mutations should
be offered to all patients with suspected genetic disease (18).
With presymptomatic detection of genetic predisposition
to this syndrome, patients can be followed with periodic
clinical tumor surveillance for expression of the disease as
well as for recurrence after treatment or progression of the
disease; knowledge of carrier status enables early interven-
tion (3).
Genotype–phenotype correlation regarding the severity of
PHPT in MEN1 cannot be identified (18,19) but knowledge
decreases the uncertainty and anxiety in the patient and
allows focused surveillance by the physician.
Parathyroid tissue
Generally the PHPT is caused by a multiglandular disease
and the parathyroid glands can become hyperplastic or
develop adenomas. The growth of the glands is asynchro-
nous and asymmetric (18), as each gland is considered to be
a monoclonal lesion in which the germline mutation in the
MEN1 gene confers on the parathyroid tissue a high
susceptibility for the development of a tumor after the
second somatic mutation (2,20).
Morphologically, parathyroid glands in MEN1 may
appear macroscopically normal, also because they can differ
in terms of volume, weight, and size (18).
Parathyroid adenomas in MEN1 can be ectopic, often
located in the thymus, rarely within the thyroid gland, in
the anterior mediastinum, in the pericardium, or surround-
ing the trachea, the esophagus, and the carotid artery
(21–23).
Supernumerary glands are frequently found in up to 20%
of MEN1 patients, although some authors do not report
supernumerary glands (18). A possible explanation for this
discrepancy may be the misinterpretation of the size, shape
or position of the parathyroid glands in MEN1 (18) because
of different surgical strategies used; some of which are more
capable of identifying supernumerary glands that would
otherwise go unnoticed (24).
Biochemistry and bone mineral density
In young MEN1 patients, PHPT is often asymptomatic;
mild ionized hypercalcemia with parathyroid hormone
(PTH) within the normal range is typical (25).
However, it should be remembered that PHPT is defined
as an excess of PTH with consequent increase in bone
turnover, leading to a reversible loss of cortical and
trabecular bone caused by an expansion of the remodeling
space and a loss of cortical for increased endocortical
resorption (26). MEN1 hyperparathyroid patients show
more precocious and severe bone loss compared with
patients with sporadic PHPT (27–31).
Surgical approaches
The optimal surgical approach in PHPT in MEN1 is still
under discussion. The choice being between: subtotal
parathyroidectomy with removal of at least three to three
and a half glands; and total parathyroidectomy with
removal of all parathyroid glands and autologous para-
thyroid tissue graft.
Subtotal parathyroidectomy requires the identification of
all parathyroid glands and the leaving of a remnant the size
of a normal parathyroid, approximately 20–30 mg. The
dissection must be meticulous to preserve the delicate single
end-artery vascular supply to the parathyroid remnant. The
parathyroid tissue left in situ should be prepared before
resection of the remaining glands, to avoid bleeding and
ischemia. Moreover, this residue must be marked with a
non-absorbable suture or a surgical clip for future identifi-
cation. It may be useful to suture the residual remnant gland
away from the recurrent laryngeal nerve to facilitate
reoperative surgery in case of persistent or recurrent disease
(18,32,33).
Total parathyroidectomy provides identification and
resection of all four glands followed by a parathyroid
heterotopic auto-implant in the non-dominant forearm (20–
25 pieces, 1 mm each, of fresh parathyroid tissue implanted
in one to five pockets created in the brachioradialis muscle).
This surgical approach must be accompanied by intrao-
perative histologic examination, to qualify and confirm the
presence of parathyroid tissue in the removed tissues, and
by rapid intraoperative PTH evaluation (18,32,33).
Reoperative debulking surgery of the forearm graft for
recurrent disease can be performed under local anesthesia.
Prophylactic transcervical thymectomy should be per-
formed in all patients to remove possible intrathymic
supernumerary parathyroid glands and prevent the devel-
opment of thymic carcinoid.
Both procedures should include a meticulous search for
ectopic parathyroid tissue, which is commonly encountered
within the thymus, mediastinum, carotid sheath, and in the
tracheo-esophageal groove (21–23).
Extensive surgery is burdened by an increased risk of
permanent hypoparathyroidism (hypocalcemia) and recur-
rent laryngeal nerve injury. Acute hypoparathyroidism may
cause mild to severe neuromuscular symptoms ranging
from neuromuscular irritability to seizures. Less extensive
surgery yields a higher risk of recurrent disease requiring
re-intervention, which increases the risk of more complica-
tions. In this latter intervention, multiple operations are
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morbidity (18,32,33).
It should be noted that in the hands of an expert surgeon
the rate of persistent disease in MEN1-associated PHPT is
less than 20%, but this may rise to 40–60% for surgeons with
less experience. For example, some MEN1 patients may
have only a single macroscopically abnormal gland and
might undergo inadequate surgery (34).
DISCUSSION
The optimal treatment of PHPT in MEN1 is parathyr-
oidectomy, as it reduces the risk of kidney stones, fractures
(improved bone mineral density), and potential cardiovas-
cular morbidity, improving quality of life and reducing
gastrin production in MEN1 patients who also have a
gastrinoma (35).
Some authors think that parathyroid surgery in patients
with MEN1 should be thought of as a debulking or
palliative procedure because long-term recurrence is inevi-
table. Surgery being indicated to treat and prevent the
complications of hyperparathyroidism (24).
There are also disputes about surgical timing in patient
with MEN1. The surgical indication for PHPT is obvious in
patients with symptoms or with severe hypercalcemia; and
in these circumstances there appears to be a good risk/
benefit balance. However, if MEN1 syndrome has not been
diagnosed preoperatively and if an experienced surgeon is
not available, then surgical treatment might not be appro-
priate (18).
In young patients with asymptomatic, mild hypercalce-
mia the timing of surgery is controversial, given that
recurrence rates increase in relation to the follow-up time.
According to our experience, biochemical screening for
hyperparathyroidism is recommended, as well as for the
other MEN1-related tumors, and it should be performed
regularly in carriers of an MEN1 mutation. This is because
clinical manifestation can be mild for long periods of time,
but a lack of regular screening may result in the delay of
diagnosis and in the development of complications (36).
Total serum calcium concentration corrected for albumin
level or ionized calcium fraction was proposed as a single
sufficient screening test for hyperparathyroidism in MEN1
(37). However, increased PTH has been observed in MEN1
patients with mild PHPT even in the absence of hypercal-
cemia, making it necessary to include serum PTH concen-
tration measurement in the screening program (38).
Imaging is not necessary for the diagnosis of parathyroid
disease in MEN1 for known multiglandular involvement,
but the presence of an experienced MEN1 surgeon is
certainly recommended (14).
Assessment of bone mass loss by densitometry is essential
in PHPT, mostly in MEN1 patients who have PHPT during
the bone mass accretion period (26–31). Lourenc ¸o et al. (39)
clearly indicated that bone demineralization in MEN1 PHPT
patients was early in onset, progressive, frequent, extensive,
and severe. Surgery is the most effective way to preserve
bone mass in patients with MEN1 PHPT (20).
Therefore, surgery is recommended in young asympto-
matic patients in whom the serum calcium values are more
than 1 mg/dl over the upper-normal limit and whose bone
mineral density values are lower than –2.5 T-score.
Early parathyroidectomy predisposes the patient to an
earlier recurrence of hyperparathyroidism and the possibility
of progressively challenging reoperations. Late surgical
interventions are easier because of the glands’ more visible
enlargement, but hypercalcemic complications increase.
The diagnosis of MEN1-associated PHPT should be
confirmed by genetic testing. Carriers of MEN1 mutations
require regular screening, regardless of the presence of
hyperparathyroidism from the second decade of life, it
being difficult to establish a genotype–phenotype relation.
When gene carriers are studied prospectively, biochemical
evidence of neoplasia can be detected as early as 5–10 years
before clinically evident disease, allowing for early surgical
intervention and therefore dramatically reducing both the
morbidity and the mortality related to the syndrome.
Surgery remains the main method of PHPT management
in MEN1, despite the high recurrence rate with the need for
repeat procedures. Some controversies surround the opti-
mal surgical technique for MEN1 PHPT. The optimal timing
for surgery remains controversial and must be assessed case
by case without forgetting that the complications of PHPT in
MEN1 are early in onset and more severe than in sporadic
PHPT. Medical therapy with the goal of bone preservation is
an option for patients without symptoms, and calcimimetics
effectively normalize calcium levels only with specific
indications.
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